# V1 Empirics Check — openai/gpt-oss-120b (Variant C)

**Model:** openai/gpt-oss-120b
**Variant:** C
**Date:** 2026-03-25T13:02:46.856997

---

**1. Idea Fidelity**  
The submitted manuscript follows the original manifest closely. It uses the staggered 2016‑2021 wave of MAID enactments, the CMS Medicare Geographic Variation Public‑Use File (county‑year panel, 2014‑2023), and a Callaway‑Sant’Anna (2021) difference‑in‑differences (DiD) design. The paper retains all key elements of the proposed identification strategy: (i) treatment defined as a state‑level “MAID in effect” indicator, (ii) never‑treated states as the control group, (iii) exclusion of the four early‑adopting states, and (iv) focus on hospice, inpatient, total Medicare spending and ER utilization as outcomes. The only minor deviation is the addition of a “triple‑difference” check that uses SNF spending as a within‑county control; this does not detract from the core design. Overall, the paper delivers the research question, data source, and methodological approach outlined in the manifest.

---

**2. Summary**  
The paper investigates whether the legalization of medical aid in dying (MAID) alters end‑of‑life Medicare spending patterns. Using a county‑level staggered DiD across seven states that adopted MAID between 2016 and 2021, the author finds essentially null effects on hospice spending, inpatient spending, total Medicare spending, and ER utilization. The analysis highlights the pitfalls of the conventional two‑way fixed‑effects estimator in staggered settings, showing a sign reversal for ER visits that disappears when a heterogeneity‑robust estimator and wild‑cluster bootstrap inference are employed.

---

**3. Essential Points**  

1. **Power & Precision of Null Findings**  
   - The point estimates are close to zero, but the accompanying standard errors (e.g., SE ≈ 9.9 for hospice, 25.1 for inpatient) imply 95 % confidence intervals of roughly ± 20 USD and ± 50 USD respectively. Given the mean hospice spending of ~$260 per capita, a $20 change corresponds to an 8 % shift—economically meaningful. The paper should more explicitly quantify the minimum detectable effect (MDE) and argue that the sample size is sufficient to rule out policy‑relevant changes.  

2. **Cluster Inference with Few Treated States**  
   - The author correctly uses wild‑cluster bootstrap, but the main tables present only conventional clustered SEs (state‑level) and the bootstrap *p*‑values in brackets. For a setting with only seven treated clusters, the bootstrap confidence intervals should be reported alongside the point estimates, and the bootstrap *t*‑statistics should be shown to confirm that the conventional SEs are not severely downward‑biased.  

3. **Parallel‑Trends Evidence**  
   - The manuscript states that event‑study plots “show no evidence of differential pre‑trends,” yet the plots are omitted from the main text and not reproduced in the appendix. Given the central role of the parallel‑trends assumption, a concise figure (or table of pre‑trend coefficients with confidence intervals) should be included. Moreover, because the treatment is at the state level, visual checks of pre‑trends at the **state‑average** level (instead of county‑level noisy series) would strengthen the credibility of the design.

If these three issues cannot be satisfactorily addressed, the paper should be **rejected**; otherwise, a **revise‑and‑resubmit** is warranted.

---

**4. Suggestions**  

| Area | Recommendation | Rationale |
|------|----------------|-----------|
| **Presentation of Results** | Add a short “Effect‑size” paragraph after Table 2 that converts the ATT into percentage changes relative to pre‑treatment means (e.g., “a $3.9 increase in hospice spending represents a 1.5 % change”). Include Wald‑type confidence intervals (e.g., [$‑15, 23]) to make the economic magnitude transparent. | Readers can quickly assess whether the null is substantively meaningful. |
| **Inference Detail** | Report wild‑cluster bootstrap **confidence intervals** (e.g., 95 % BCa intervals) for each ATT. Consider also the “wild cluster bootstrap *t*” approach (Cameron, Gelbach, Miller 2008) and discuss any differences from the analytic SEs. | With only seven treated clusters, conventional SEs can be unreliable; presenting bootstrap intervals demonstrates robustness. |
| **Event‑Study Figures** | Include a figure with the Callaway‑Sant’Anna cohort‑specific event‑study estimates for hospice and inpatient spending. Show pre‑treatment periods (e.g., –5 to –1) with 95 % CI and annotate the treatment year. If the figure is too busy, provide a table of pre‑trend coefficients and *p*‑values. | Parallel trends are the cornerstone of DiD. Visual evidence will satisfy reviewers and readers. |
| **Placebo Outcomes** | Expand the placebo analysis beyond SNF and home‑health spending. Consider a “non‑terminal” aggregate (e.g., outpatient services) and a “lagged” outcome (e.g., total spending in the **following** year) to test for anticipatory or spillover effects. | A broader set of falsification tests strengthens the claim that MAID adoption is not correlated with general Medicare spending trends. |
| **Heterogeneity Exploration** | Although cohort‑specific estimates are shown in the appendix, the main text should discuss any systematic patterns (e.g., larger (though still insignificant) point estimates for the 2021 cohort). Conduct a simple interaction with baseline hospice utilization (high vs. low states) to see if the effect differs where there is more “room” to shift. | Even null overall results can mask heterogeneous impacts that are policy‑relevant. |
| **Mechanism Discussion** | The paper posits “cultural spillovers” but does not provide any direct evidence of increased advance‑directive completion or palliative‑care counseling. If feasible, merge the CMS data with state‑level AD completion rates (e.g., from the National Hospice and Palliative Care Organization) or use survey data (NHIS) to show that the hypothesized pathway does not materialize. | Demonstrating the absence of the mechanism helps explain why the fiscal null occurs and enriches the contribution. |
| **Robustness to Alternative Timing** | Test alternative definitions of the treatment year (e.g., using the date of first **prescription** issuance rather than law enactment) and a “lead‑lag” specification that allows for a gradual rollout. | MAID laws may have a lag before they affect provider behavior; checking alternative timings rules out mis‑specification. |
| **Sample Construction Clarifications** | Provide a flowchart showing how the 30,429 county‑year observations are derived (e.g., start with 33,639 rows, drop territories, drop always‑treated, drop counties with missing data). Also, discuss any potential bias from counties that appear only in some years (e.g., newly created counties). | Transparency about sample attrition is essential for reproducibility. |
| **External Validity** | Briefly discuss whether results for fee‑for‑service Medicare beneficiaries are likely to generalize to Medicare Advantage or to non‑Medicare populations (e.g., private insurers). | Policy makers may wonder about broader applicability. |
| **Software & Replicability** | Include a replication package (R or Stata code) on a public repository and mention the version of the Callaway‑Sant’Anna package used. | Journals and readers increasingly expect open code for DiD applications. |
| **Formatting & Minor Errors** | • Table 1’s “Counties” row lists 5,627 but the text says 3,056 counties; reconcile this inconsistency.<br>• In the abstract, “ER visits ($+$22.6, $t = 2.0$)” should clarify that the *t*‑statistic is based on clustered SEs.<br>• Remove the empty “Standardized Effect Sizes” table or fill it with actual numbers; as is, it adds no value. | Improves readability and avoids confusion. |

Implementing the above suggestions will turn a well‑executed null result into a paper that convincingly demonstrates both the substantive finding (no fiscal impact of MAID legalization) and the methodological lesson (importance of heterogeneity‑robust DiD with few treated clusters). The contribution is valuable for health‑policy economists and for the broader applied‑micro community
